• logo
  • Products
    • Search for Product
      • Product Name

        Keyword Search

    • Featured Products
        • LEVAMED


        • XYLAMED

          XYLAMED™ (Rx)

  • News
  • Library
  • Facilities
  • About
  • Regions
  • Contact
Bimeda US - Items filtered by date: October 2016

(Oakbrook Terrace, IL – November 18, 2016 ) Bimeda, Inc. has acquired the marketing rights to Ceva Animal Health, LLC’s portfolio of equine products in the United States. 

The U.S. portfolio comprises Tildren® (tiludronate disodium, NADA# 141-420), Altrenogest (ANADA# 200-481), ConfidenceEQ®, and PentosanEQ™. Bimeda also acquired the marketing rights for Tildren in Canada. 

“This agreement is a key milestone in Bimeda’s strategic expansion into the Equine market. With a large portfolio of complementary products, Bimeda will now be in a strong position to serve the needs of equine customers in North America”, said Alan Kelly, Director of Commercial Development for Bimeda North America.

For more information please visit BimedaEquine.com.

Published in News Archive